Simon Lovestone

I am a clinician scientist working mostly on Alzheimer’s Disease but also on other neurodgeneration disorders such as Parkinson’s disease. Ultimately my group’s research is focussed on trying to find treatments, especially in the early preclinical or prodromal phase of disease. A successful therapy in this phase would delay or prevent symptoms; sometimes referred to as secondary prevention.

With this end in mind my team’s research includes understanding mechanisms and developing novel therapeutic targets, on finding biomarkers to facilitate clinical trials in the early phases of disease and the use of informatics to derive useful information from large datasets, both molecular and clinical.

The lab group’s work is described here and the ARUK Oxford Drug Development Institute led by Lovestone and Bountra is here. 

You can find me on Twitter here.